Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cooling effect of evaporative misters in outdoor restaurant areas: case study of Novi Sad, Serbia.

International journal of biometeorology·2026

Same author

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium.

Heliyon·2024

Same author

Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration.

Journal of endocrinological investigation·2024

Same author

Drug allergy labels in elective surgical patients: what do patients and their anaesthetists think about penicillin allergy labels?

British journal of anaesthesia·2024

Same author

The phenotype of Graves' orbitopathy is associated with thyrotropin receptor antibody levels.

Journal of endocrinological investigation·2023

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Glucocorticoid effect on insulin sensitivity: a time frame.

M Zarkovic¹, B Beleslin, J Ciric

¹Institute of Endocrinology, 11000 Belgrade, Serbia. mzarkov@eunet.yu

Journal of Endocrinological Investigation

|April 11, 2008

Summary

This summary is machine-generated.

Glucocorticoids rapidly induce insulin resistance in humans within approximately 4 hours. This effect on insulin sensitivity remains consistent throughout prolonged glucocorticoid treatment.

More Related Videos

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Related Experiment Videos

Last Updated: Jul 6, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Area of Science:

Endocrinology
Metabolic Research

Background:

Glucocorticoids are known to cause insulin resistance.
The precise timeline for the onset of glucocorticoid-induced insulin resistance in humans remains unclear.

Purpose of the Study:

To investigate the time scale of pharmacologic glucocorticoid doses on human insulin sensitivity.
To determine how quickly insulin resistance develops and if it changes with extended treatment.

Main Methods:

Utilized euglycemic hyperinsulinemic clamp (EHGC) and short insulin tolerance test (SITT) to measure insulin sensitivity.
Subjects received methylprednisolone infusions and oral prednisone for Graves' orbitopathy.
Measurements were taken before, during, and after glucocorticoid administration.

Main Results:

A significant reduction in insulin sensitivity was observed approximately 4 hours after initiating glucocorticoid infusion.
Insulin sensitivity did not significantly change during the first 30 minutes of infusion.
The observed insulin resistance persisted for 2 months of continuous glucocorticoid treatment.

Conclusions:

Glucocorticoid-induced insulin resistance develops rapidly in humans, within about 4 hours.
The degree of insulin resistance does not appear to change with extended glucocorticoid therapy.